Literature DB >> 22143279

Vascular Ehlers-Danlos syndrome: pathophysiology, diagnosis, and prevention and treatment of its complications.

Natalia Beridze1, William H Frishman.   

Abstract

The Ehlers-Danlos syndrome consists of a group of inherited connective tissue disorders caused by defects in the synthesis of collagen. The vascular type 4 form of Ehlers-Danlos syndrome (VEDS) is associated with serious vascular complications in young adults, such as the spontaneous rupture of large-caliber and medium-caliber arteries, often without true aneurysm formation or dissection. VEDS is inherited as an autosomal dominant trait that is caused by mutations in the COL3A1 gene. It affects the synthesis and structure of the pro a1 (III) chain of collagen type III, which causes vascular wall weakness. The diagnosis of VEDS is made from major and minor clinical criteria and can be confirmed by abnormalities in procollagen production and molecular genetic testing. Recently, the results of a study using the b-blocker celiprolol demonstrated a reduction in vascular complications of VEDS. The mechanisms of benefit may be related to a reduction in vascular hemodynamic stress with exercise and/or through a reduction in transforming growth factor-b. Inhibitors of the renin-angiotensin system may also be beneficial in VEDS. Surgery may be beneficial in treating the complications of VEDS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22143279     DOI: 10.1097/CRD.0b013e3182342316

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  13 in total

1.  Homozygous factor V Leiden mutation in type IV Ehlers-Danlos patient.

Authors:  Marwan Refaat; Mostafa Hotait; Brion Winston
Journal:  World J Clin Cases       Date:  2014-03-16       Impact factor: 1.337

2.  Images in COPD: Idiopathic Emphysema in a Never Smoker.

Authors:  Stephan S Leung; Patrick Lee; Jessica E Most; Baskaran Sundaram
Journal:  Chronic Obstr Pulm Dis       Date:  2020-04

3.  Type IV Ehlers-Danlos syndrome presenting as recurrent, bilateral carotid dissections.

Authors:  Richard James Booth Ellis; Maqsud Salehin; Rui Zhou; Mohammad Somauroo
Journal:  BMJ Case Rep       Date:  2012-12-12

Review 4.  Unruptured intracranial aneurysms: development, rupture and preventive management.

Authors:  Nima Etminan; Gabriel J Rinkel
Journal:  Nat Rev Neurol       Date:  2016-11-03       Impact factor: 42.937

5.  Genetic dissection of marfan syndrome and related connective tissue disorders: an update 2012.

Authors:  S Hoffjan
Journal:  Mol Syndromol       Date:  2012-06-12

6.  A Lethal Complication after Coronary Angiography in a Patient with Ehlers-Danlos Syndrome.

Authors:  Yen-Chou Chen; Cheng-Chih Chung; Pai-Feng Kao; Ming-Hsiung Hsieh
Journal:  Acta Cardiol Sin       Date:  2013-05       Impact factor: 2.672

7.  miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.

Authors:  Enrique Fuentes-Mattei; Recep Bayraktar; Taghi Manshouri; Andreia M Silva; Cristina Ivan; Diana Gulei; Linda Fabris; Nayra Soares do Amaral; Pilar Mur; Cristina Perez; Elizabeth Torres-Claudio; Mihnea P Dragomir; Adriana Badillo-Perez; Erik Knutsen; Pranav Narayanan; Leonard Golfman; Masayoshi Shimizu; Xinna Zhang; Wanke Zhao; Wanting Tina Ho; Marcos Roberto Estecio; Geoffrey Bartholomeusz; Ciprian Tomuleasa; Ioana Berindan-Neagoe; Patrick A Zweidler-McKay; Zeev Estrov; Zhizhuang J Zhao; Srdan Verstovsek; George A Calin; Roxana S Redis
Journal:  JCI Insight       Date:  2020-01-16

8.  Celiprolol: A Unique Selective Adrenoceptor Modulator.

Authors:  James J Nawarskas; Angela Cheng-Lai; William H Frishman
Journal:  Cardiol Rev       Date:  2017 Sep/Oct       Impact factor: 2.644

9.  Pleuritic chest pain in a young female: a reminder for acute health care providers.

Authors:  Aibek E Mirrakhimov; Alaa M Ali; Carolyn Stroncek
Journal:  Case Rep Emerg Med       Date:  2014-08-27

Review 10.  Vascular phenotypes in nonvascular subtypes of the Ehlers-Danlos syndrome: a systematic review.

Authors:  Sanne D'hondt; Tim Van Damme; Fransiska Malfait
Journal:  Genet Med       Date:  2017-10-05       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.